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Glucagon-like peptide-1 (GLP-1) is a potent gluco-incretin hormone, which plays a central
role on pancreatic beta cell proliferation, survival and insulin secreting activity and whose
analogs are used for treating hyperglycemia in type 2 diabetes mellitus. Notably, abnormal
insulin signaling affects all the above-mentioned aspects on pancreatic beta cells. The aim
of our study was to investigate whether the protective effects of GLP1-1 on beta cells are
affected by altered insulin receptor signaling. To this end, several effects of GLP-1 were
studied in INS-1E rat beta cells transfected either with an inhibitor of insulin receptor function
(i.e., the Ectonucleotide Pyrophosphatase Phosphodiesterase 1, ENPP1), or with insulin
receptor small interfering RNA, as well as in control cells. Crucial experiments were carried
out also in a second cell line, namely the βTC-1 mouse beta cells. Our data indicate that in
insulin secreting beta cells in which either ENPP1 was up-regulated or insulin receptor was
down-regulated, GLP-1 positive effects on several pancreatic beta cell activities, including
glucose-induced insulin secretion, cell proliferation and cell survival, were strongly reduced.
Further studies are needed to understand whether such a scenario occurs also in humans
and, if so, if it plays a role of clinical relevance in diabetic patients with poor responsiveness
to GLP-1 related treatments.
Introduction
Glucagon-like peptide 1 (GLP-1) is a potent gluco-incretin hormone secreted from the enter-
oendocrine L cells in response to food ingestion [1], which exerts a positive effect on insulin
secretion, beta cell proliferation and apoptosis [2, 3]. Based upon this main physiological role,
incretin-based therapies have become an attractive tool for treating hyperglycemia in patients
with type 2 diabetes mellitus. Unfortunately, up to 60% patients are unresponsive to such ther-
apies for so far unknown reasons [4–8]. Several studies in animal models have consistently
reported that abnormal insulin signaling affects insulin secretion, proliferation and survival of
beta cells [9–11]. Along the same line of evidences, human non-synonymous genetic polymor-
phisms (i.e. ENPP1 K121Q, IRS-1G972R and TRIB3Q84R) affecting insulin signaling pathway
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[12–15] are able to reduce, both as singly considered and even more in combination, insulin
secretion in vivo [16], in isolated human islets [16–19] and in cultured beta-cells [18–21].
Thus, an intriguing scenario has emerged suggesting that abnormalities impairing insulin sig-
naling play a role on glucose homeostasis not only by reducing insulin sensitivity in peripheral
tissues (i.e. liver and skeletal muscle), but also by affecting several aspects of beta cells function-
ality [20–21].
Several studies have shown that there is a cross talk between G-protein coupled receptors,
including GLP-1 receptor, and tyrosine-kinase receptors, including insulin receptor [22–24].
Whether in beta cells the protective effect of GLP-1 on insulin secretion, proliferation and
survival is affected by abnormal insulin signaling is a fascinating possibility with potential clin-
ical relevance, which has never been addressed.
To answer this question, rat and mouse cultured beta cells were manipulated either by up-
regulating ENPP1, a known inhibitor of insulin receptor signaling [21, 25] or by down-regulat-
ing insulin receptor itself.
Materials and methods
Antibodies and reagents
Glucagon-like peptide-1 (7–36) amide and antibody against actin were obtained from Sigma
Aldrich (St. Louis, MO, USA).
Antibodies anti-phospho-44/42-mitogen-activated protein kinase (ERK 1/2), anti total
ERK 1/2, anti phospho-AKT, anti total AKT, anti-ENPP1 and anti-Insulin Receptor were pur-
chased from Cell Signaling Technology (New England Biolabs, Beverly, MA). Anti GLP1-R
antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
All other chemicals were of the highest grade commercially available.
Cell culture
Rat insulin-secreting INS-1E cells (a kind gift from C. B. Wollheim, Department of Cell Physi-
ology and Metabolism, University of Geneva, Geneva, Switzerland) were grown in monolayer
cultures in regular RPMI 1640 medium supplemented with 10% heat-inactivated Fetal Bovine
Serum (FBS), 10 mmol/l HEPES, 100 IU/ml penicillin, 100μg/ml streptomycin, 1 mmol/l
sodium pyruvate, 2 mmol/l L-glutamine and 50μmol/l ß-mercaptoethanol in a humidified
atmosphere (5% CO2/95% air) at 37˚C. βTC-1 beta cell line, derived from transgenic mouse
insulinoma, was grown in Dulbecco’s modified Eagle’s medium containing 25 mmol/l glucose
supplemented with 15% horse serum (HS), 2.5% heat inactivated FBS, 1 mmol/l sodium pyru-
vate, 100 IU/ml penicillin, 100μg/ml streptomycin, 2 mmol/l L-glutamine and 50μmol/l ß-
mercaptoethanol in a humidified atmosphere (5% CO2/95% air) at 37˚C. In studies involving
serum-starvation, serum was replaced by 0.1% BSA in medium containing 3 mmol/l glucose.
We conducted all the experiments in starvation because both INS-1E and βTC-1 are insuli-
noma-derived cells, constitutively producing insulin. As a matter of fact, in these cells starva-
tion reduced, but not abolished, insulin secretion, with insulin concentration in the medium
being in the range of 0.8–1.0 nmol/L.
Plasmid and transfections
The full-length cDNA of ENPP1-Q121 was generated by site directed mutagenesis as previ-
ously described [13] and cloned in mammalian expression vector pRK7 [13]. INS-1E cells
were either transfected with a plasmid (pRK7-neo) containing the neomycin resistance gene
(INS1E-neo) or with the pRK7-neo plus the ENPP1-Q121 cDNA (INS-1E-ENPP1) by using
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the Fugene Transfection Reagent (Roche Germany) [19] and a clone overexpressing ENPP-1
(i.e. INS-1E-ENPP1) was selected (Fig 1A, S1 Fig). Transient transfections with pRK7-neo
(βTC1-neo) and ENPP1-Q121 (βTC1-ENPP1) were carried out in βTC-1 cells (Fig 1B, S1 Fig).
The insulin receptor knock-down in INS-1E cells was obtained by small interfering RNA
(siRNA) transfection. A pool of 3 different siRNAs was transfected in INS1-E cells for insulin
receptor RNA interference, by using Lipofectamine RNAiMax (Life Technologies). A no
targeting siRNA (scramble) was used as negative control, according to the manufacturer’s
instruction. A significant down-regulation of insulin receptor expression (83±5% reduction)
was obtained, as compared to scramble control cells (Fig 1C, S1 Fig).
Glucose induced insulin secretion
Glucose induced insulin secretion was evaluated as previously described [19, 25] Briefly, 3x105
cells/well were seeded in 24-well plates and grown for 72 hours. The day of the experiment,
cells were washed twice with glucose-free Krebs solution pH 7.4 and pre-incubated (1 hour,
37˚C, 5% CO2) in Krebs buffer containing 2.8mmol/l glucose. Insulin secretion was deter-
mined in the presence of 2.8 mmol/l or 16.6 mmol/l glucose in the absence or presence of
GLP-1 (100 nmol/l). After 60 minutes at 37˚C, aliquots of supernatant were taken for measur-
ing insulin concentration, while total protein content was determined by using BCA protein
assay (Pierce, Rockford, IL, USA), as previously described [19]. Rat/mouse insulin was mea-
sured by ELISA (Millipore, Billerica, MA, U.S.A).
Cell proliferation
Briefly, a triplicate of 104 cells/well was seeded in 24-well plates and grown for 72 hours. Cells
were switched to serum free medium for 12 hours and then incubated for 48 hours in the
Fig 1. GLP-1 fails to increase insulin secretion in ENPP-1 transfected cells. INS-1E (panel A) and βTC-1 (panel B) cells, either transfected
with neomicine (neo) or ENPP1 gene variant, were exposed to 100 nmol/l GLP-1 (60 min, 37˚C) and glucose induced insulin secretion measured.
Values are expressed as means ± S.D. of five independent experiments; *p<0.05 compared to neo-transfected cells at 2.8 mmol/l glucose;
**p<0.05 compared to neo cells at 16.6 mmol/l glucose.
https://doi.org/10.1371/journal.pone.0181190.g001
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absence or presence of GLP-1 (100 nmol/l). Cell proliferation was assessed by measuring DNA
synthesis in proliferating cells by the pyrimidine analog 5-bromo-2’-deoxyuridine (BrdU)
incorporation assay (Perkin Elmer, Waltham, MA, USA). BrdU labeling was performed for
the 48-hour incubation period in the presence or absence of GLP-1 (100 nmol/l).
Apoptosis
Apoptosis was measured by the caspase-3/7 activity. Cells (104 cells/well) seeded in 96-well
plates in triplicate and grown for 72 hours, were switched to serum free medium for 12 hours
and then incubated (2 hours at 37˚C) with staurosporine (0.25 μmol/l) in the absence or pres-
ence of GLP-1 (100 nmol/l). Caspase 3/7 enzyme activity was evaluated by using Caspase-Glo
3/7 Assay (Promega, Madison, WI, USA) according to manufacturer’s protocol.
In addition, apoptosis was quantitatively detected by the surface exposure of phosphatidyl ser-
ine in apoptotic cells by using an Annexin V-PE and 7-Amino-actinomycin D (7-AAD) double
coloration (BD Biosciences, Labware, Bedford, MA). Briefly, (5 x 105 cells/well) INS-1E trans-
fected cells were seeded in six-well and grown for 72 hours. The cells were switched to serum
free medium for 12 hours and then incubated (2 hours at 37˚C) with staurosporine (0.25 μmol/l)
in the absence or presence of GLP-1 (100 nmol/l). Cells were washed and suspended at a concen-
tration of 1 x 106 cells/ml in Annexin V Binding Buffer and then incubated with annexin V and
the vital dye 7-AAD for 15 min at room temperature. Apoptosis was assessed using a FACS cali-
bur flow cytometry (Becton Dickinson, San Jose, CA, USA). Annexin V staining was done in
conjunction with the vital dye 7-AAD to differentiate early apoptosis (annexin V+, 7-AAD-)
from late apoptosis (annexin V+, 7-AAD+).
Western blot analysis
For Western Blot (WB) analysis, cells were seeded in 60-mm dishes at a density of 2 x 106 cells,
grown for 72 hours and then serum-starved (12 hours, at 37˚C). Cells were then incubated (2
hours at 37˚C) in the absence or presence of GLP-1 (100 nmol/l), lysed in ice-cold lysis buffer
and protein concentration determined by BCA. Proteins (30μg) were then separated on SDS-
polyacrylamide gel and membrane blocked with 5% non-fat dried milk (1 h room tempera-
ture) and incubated with primary (1:1000, O/N, 4˚C) and then with secondary antibodies
(1:2000, 1h, room temperature). Peroxidase activity was detected by films using an enhanced
chemiluminescence (ECL) detection reagent (GE Healthcare Life Science).
Statistical analysis
Results are expressed as means ± S.D. for n independent experiments. Statistical differences
between groups were evaluated by Student’s t test for unpaired comparison or by ANOVA, as
appropriate. A p value less than 0.05 was considered to be significant.
Results
GLP-1 effect on insulin secretion
In INS-1E-neo cells, insulin secretion was clearly increased by high glucose concentration (i.e.
16.6 mmol/l as compared to 2.8 mmol/l glucose, considered as the baseline condition, Fig 1A).
Under both low and high glucose concentrations, insulin secretion was more than doubled by
100 nmol/l GLP-1 co-incubation (Fig 1A). In INS1-E-ENPP1-cells (see methods and Fig 1A,
S1 Fig for the effect of transfection experiments), in which insulin receptor signaling is affected
[19], glucose-induced insulin secretion and GLP-1 stimulatory effect were totally blunted, with
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virtually no differences on insulin secretion across the four different experimental conditions
(Fig 1A).
Although some difference was observed in the baseline (2.8 mM glucose) condition, very
similar results were obtained at 16.6 mM glucose in a second cell line, namely mouse βTC-1
(Fig 1B), thus showing that our finding was not restricted only to rat beta cells.
GLP-1 effect on beta cell proliferation
In INS-1E-neo cells, GLP-1 (100 nmol/l) significantly increased DNA synthesis but this effect
was totally abolished in INS-1E-ENPP1 cells (Fig 2A).
Similarly, 100 nmol/l GLP-1 significantly increased DNA synthesis in βTC-1-neo cells,
while no effect at all was observed in βTC-1-ENPP1 cells (Fig 2B).
GLP-1 effect on apoptosis
In INS-1E-neo cells, staurosporine treatment (0.25 μmol/l, 2 hours) greatly increased 3/7 cas-
pase activity (Fig 3A). This deleterious effect was significantly (p<0.05) reduced by 100 nmol/l
GLP-1 (Fig 3A). Quite notably, in INS-1E-ENPP1 cells, staurosporine deleterious effect on
apoptosis was markedly increased and only mildly and not significantly reduced by 100 nmol/l
GLP-1 (Fig 3A). Overall, caspase 3/7 activity was significantly increased in ENPP1-cells in
respect to their counterpart neo-cells (p<0.05 for all three experimental conditions). Similar
results were obtained by using FACS analysis, with higher baseline apoptosis (p<0.05) and no
significant GLP-1 anti-apoptotic effect observed in ENPP1-, as compared to neo-cells (data
not shown).
Even more striking were the results obtained in βTC-1 cells with staurosporine-induced
apoptosis being higher and GLP1-1 protective effect being heavily blunted in ENPP1-cells as
compared to neo-cells (Fig 3B). Of note, as a whole, βTC-1 cells showed a much higher base-
line level of apoptosis than INS-1E cells.
Fig 2. GLP-1 fails to increase cell proliferation in ENPP-1 transfected cells. Proliferation was assessed by BrdU incorporation in
INS-1E (panel A) and βTC-1 (panel B) cells, either transfected with neo or ENPP-1 gene variant. Cells were starved for 12 hours and
then incubated for 48 hours in the absence or presence of 100 nmol/l GLP-1. Values are means ± S.D. of four independent experiments.
* p<0.05 for INS-1E and for βTC-1 compared with untreated INS-1E-neo or βTC-1-neo cells.
https://doi.org/10.1371/journal.pone.0181190.g002
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GLP-1 effects on insulin secretion, proliferation and apoptosis in insulin
receptor knockdown cells
In order to get deeper insights about the role of insulin receptor signaling on GLP-1 effects in
insulin secreting beta cells, INS-1E cells were transfected with insulin receptor siRNA, which
caused a significant reduction of insulin receptor expression levels (-83±5% p<0.001; see Fig
1C, S1 Fig for the effect of transfection experiments).
In contrast to scramble control cells, insulin receptor siRNA cells showed no stimulatory
100 nmol/lGLP-1 effect on 16.6 mmol/l glucose-induced insulin secretion (Fig 4A).
Furthermore, while 100 nmol/l GLP-1 significantly increased DNA synthesis in scramble
cells, no such effect was observed in insulin receptor SiRNA transfected cells (Fig 4B).
Finally, a significant anti-apoptotic effect of 100 nmol/l GLP-1 was observed in scramble
but not in insulin receptor siRNA cells (Fig 4C). It is of note that, in insulin receptor siRNA
cells, caspase 3/7 activity was significantly higher than in scramble control cells under FBS,
staurosporine alone and staurosporine in the presence of GLP-1 100 nmol/l (p<0.05 for all
three conditions).
Data obtained in insulin receptor down-regulated cells strongly reinforce those in cells
overexpressing ENPP1 and altogether demonstrate that insulin receptor signaling is critical for
the protective GLP-1 effect on beta-cell function and survival.
Fig 3. GLP-1 fails to rescue apoptosis in ENPP1 transfected cells. Apoptosis was assessed by caspase 3/7 activity, in INS-1E
(panel A) and βTC-1 (panel B) cells, either transfected with neo or ENPP-1 gene variant. Cells were treated with staurosporine
(0.25 μmol/l, 2 hours) in the absence or presence of 100 nmol/l GLP-1. Treatment with GLP-1 significantly decreased apoptosis induced
by staurosporine in INS-1E-neo and in βTC-1-neo cells but not in INS-1E-ENPP1 and in βTC-1-ENPP1 cells. Values are expressed as
means ± SD in INS-1E (n = 7) in βTC-1 (n = 8) independent experiments, each comprising three wells. (* p<0.05 compared with
untreated INS-1E-neo or βTC-1-neo cells; § p<0.005 compared with INS-1E-neo or βTC-1-neo cells treated with staurosporine; ˚ p<0.05
compared with untreated INS-1E-ENPP1 or βTC-1-ENPP1; # p< 0.05 compared with INS-1E-neo or βTC-1-neo cells treated with
staurosporine; $ p< 0.05 compared with INS-1E-neo or βTC-1-neo cells exposed to GLP1).
https://doi.org/10.1371/journal.pone.0181190.g003
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GLP-1 intracellular signaling
In order to get some insights on the mechanisms underlying the influence of insulin receptor
down regulation on GLP-1 effects on insulin secreting beta cells, AKT and ERK phosphoryla-
tion was investigated in INS-1E cell, under several conditions.
Fig 5, panel A, shows that, as compared to unstimulated INS-1E neo-cells, AKT phosphory-
lation was markedly increased by GLP-1 100 nmol/l stimulation (88% increase, p< 0.05).
Conversely, in INS-1E ENPP1-cells, in which baseline AKT phosphorylation was markedly
reduced, GLP-1-effect was totally abolished.
Very similar results were obtained when ERK phosphorylation was studied (Fig 5, panel B).
Notably, no changes in GLP-1 receptor protein expression were observed, across the same
experimental conditions (S1 Fig).
Taken together, these data strongly suggest that the effect of insulin receptor signaling on
GLP-1 effects is mainly operating at GLP-1 post-receptor signaling level.
Discussion
We have previously reported that rat cultured insulin secreting beta cells overexpressing
ENPP1, an insulin receptor inhibitor, are characterized by abnormal insulin receptor signaling
as well as reduced glucose-induced insulin secretion and cell survival [19]. Such deleterious
effects are especially observable when the Q121 gain-of-function variant is operating [19]. In
this study we went further on the role of insulin signaling on pancreatic beta cell activities and,
Fig 4. GLP-1 effects on insulin secretion, proliferation and apoptosis are impaired in insulin receptor knockdown cells. Panel A. Insulin
secretion in INS-1E cells, transfected with insulin receptor siRNA. Cells were incubated with 2.8 or 16.6 mmol/l glucose in the absence or presence
of GLP-1 (100 nmol/l). Values are expressed as means ± SD of three independent experiments (*p<0.05 vs. scramble cells exposed to 2.8 mmol/l
glucose; ** p<0.05 vs. scramble cells exposed to 2.8 mmol/l glucose plus 100 nmol/l GLP-1; #vs. scramble cells exposed to 16.6 mmol/l glucose;
˚p<0.05 vs. siRNA cells exposed to 2.8 mmol/l glucose; ˚˚ siRNA cells exposed to 2.8 mmol/l glucose plus 100 nmol/l GLP-1). Panel B. Cell
proliferation, assessed by BrdU incorporation, in INS-1E cells transfected with insulin receptor siRNA. Cells were switched to serum free medium
for 12 hours and then incubated for 48 hours in the absence or presence of GLP-1 (100 nmol/l). Values are expressed as means ± SD of four
independent experiments, each comprising three wells (c¸ p<0.05 vs. untreated scramble cells). Panel C. Apoptosis, assessed by caspase 3/7
activity, in INS-1E cells transfected with insulin receptor siRNA. Cells were treated with staurosporine (0.25μmol/l, 2 hours) in the absence or
presence of 100 nmol/l GLP-1. Treatment with GLP-1 significantly decreased apoptosis induced by staurosporine in scramble control cells but not
in siRNA transfected cells. Values are expressed as means ± SD of nine independent experiments, each comprising three wells. (§ p<0.05 vs.
untreated scramble or siRNA transfected cells; # p<0.05 vs. scramble cells treated with staurosporine in the absence of GLP-1).
https://doi.org/10.1371/journal.pone.0181190.g004
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by using the same naturally occurring, biological tool (i.e. ENPP1-Q121), report for the first
time that an integral insulin receptor signaling is essential for the protective effects of GLP-1
on insulin secretion, cell proliferation and survival to be fully exerted. Identical conclusions
can be drawn by experiments in which insulin receptor down-regulation was obtained by
small interfering RNA transfection.
The exact mechanisms through which insulin signaling exerts such a permissive effect on
GLP-1 action remains elusive. Recent studies have shown that signal transduction, initiated by
G-protein coupled receptors and tyrosine-kinase receptors, is organized in mutually related
signaling cassettes, leading to a crosstalk between the two signaling pathways [24]. As a matter
of fact, our data showing that intact insulin receptor signaling is essential for GLP-1 post-
receptor signaling is totally compatible with this scenario. Other studies reported that GLP-1
increases beta cell proliferation not only by activation of GLP-1R receptor but also by up-regu-
lation of IGF-1 receptor expression [22] and transactivation of EGF receptor [23]. Finally,
there were evidences of a critical role of IRS2 signaling in promoting exendin-4 stimulated
beta cell growth [26]. With this background in mind, it remains possible that the inhibitory
activity of reduced insulin signaling on GLP-1 effects we here observed is either directly related
to GLP-1 mechanisms of action or, conversely, referable to the more general deleterious effect
on several aspects of beta cells functionality we detected also in the absence of GLP-1.
Our present data are somehow in contrast to those of Moon et al. [27] showing that insulin
signaling pathway exerts a fine negative tuning on beta cell responsiveness to GLP-1 action.
The reasons for such discrepancy are not easy to understand. We can here only speculate that
Fig 5. GLP-1 effects on phosphorylation of Akt and ERK 1/2. Phosphorylation of Akt and p-Akt/Akt ratio (panel A) and ERK 1/2 and the
p-ERK/ERK ratio (panel B) was evaluated by western blot analysis in INS-1E. Cells were serum-starved for 12 hours and then incubated (2
hours at 37˚C) in the presence of BSA or GLP-1 (100 nmol/l). Values are means ± S.D. of four independent experiments. (* p<0.05
compared with BSA treated INS-1E-neo cells; $ vs INS-1E neo GLP-1 100 nM).
https://doi.org/10.1371/journal.pone.0181190.g005
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differences in the experimental design for obtaining abnormalities of the insulin signaling
pathways, with chemicals whose specificity is far to be demonstrated being utilized in Moon’s
study [27], have played a role.
Our study has both strengths and limitations. Among the formers is that though two totally
different established tools [27] were used to affect insulin receptor, very similar, virtually
superimposable, results have been obtained. A further strength is that wide range of GLP-1
protective effects have been investigated with the deleterious effect of abnormal insulin signal-
ing being observed across all of them. Finally, it is also of note that the most crucial experi-
ments were carried out also in a second cell line, of mouse rather than rat origin, thus making
possible to exclude that our findings are either cell- or even species- specific and conversely
suggesting they are generalizable to many experimental conditions.
Among limitations we acknowledge that no mechanistic insights, underlying the deleterious
effect of abnormal insulin signaling on GLP-1 protective effect on beta cell, have been add-
ressed. In fact, further studies are ongoing in our laboratory aimed at understanding the inti-
mate molecular mechanisms through which insulin signaling exerts its permissive effect on
GLP-1 action. Finally, it is unknown if the permissive effect of insulin receptor function on
GLP-1 action we observed in beta cells is similarly operating in other cell types, so to hypothe-
size that defective insulin receptor activity affects other important GLP-1 effects, including that
on CNS and hearth [28, 29]. In conclusion our data indicate that the overexpression of ENPP1
(an inhibitor of insulin receptor signaling) as well as the down-regulation of insulin receptor
itself, blunt GLP-1 action on beta cell insulin secretion, proliferation and survival, thus provid-
ing evidence that integral insulin receptor function is a prerequisite for such GLP-1 positive
effects to be fully expressed. Further studies are needed to understand whether this phenome-
non plays a role of clinical relevance in the not negligible proportion of diabetic patients
experiencing GLP-1 related treatments failure (4–8). More specifically, it will be of note to try
understand whether individuals carrying the ENPP1-Q121 variant (i.e. approximately 30% of
the whole population) are more prone to be poor responders to such treatments, thus allowing
to envisage a precision medicine approach for the treatment of type 2 diabetes mellitus.
Supporting information
S1 Fig. Expression of ENPP1, insulin receptor and GLP-1 receptor. Panel A. ENPP1 expres-
sion in INS-1E rat beta cells, evaluated by SDS PAGE followed by immunoblotting with an
anti ENPP1 polyclonal antibody.
Panel B. ENPP1 expression in βTC-1 mouse beta cells, evaluated by SDS PAGE followed by
immunoblotting with an anti ENPP1 polyclonal antibody. A representative experiment of
three independent ones is shown.
Panel C. Insulin receptor expression in INS-1E rat beta cells, transfected with no targeting
siRNA (scramble) or specific insulin receptor siRNA (siRNA) evaluated by SDS PAGE fol-
lowed by immunoblotting with an anti insulin receptor polyclonal antibody. A representative
experiment of three independent ones is shown.
Panel D. GLP-1 receptor expression in INS-1E cells transfected with Neo or ENPP1 evaluated
by SDS PAGE followed by immunoblotting with an anti GLP-1 receptor monoclonal antibody.
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